Apixaban suppliers?

Who manufactures Apixaban, and what are the patent implications for generic suppliers?

Apixaban is an anticoagulant medication used to prevent blood clots and strokes. It is marketed under the brand name Eliquis by pharmaceutical companies Bristol-Myers Squibb (BMS) and Pfizer.

Bristol-Myers Squibb and Pfizer: Partnership and Patent Exclusivity

BMS and Pfizer formed a partnership in 2010 to co-market and co-develop Apixaban. The companies hold patents for the medication in several countries, including the United States, Europe, and Japan [1]. According to DrugPatentWatch.com, the U.S. patent for Apixaban is set to expire in 2025 [2].

Generic Suppliers and Regulatory Challenges

Generic suppliers face significant regulatory hurdles in bringing Apixaban to market. The complexity of the patent environment and the need for regulatory approval create barriers to entry. Companies seeking to develop generic versions of Apixaban must navigate the U.S. FDA approval process, which involves demonstrating pharmacokinetic equivalence and safety [3].

Biosimilarity and Interchangeability

The approval pathway for biosimilars is separate from generic drugs. While biosimilars can enter the market earlier, the FDA requires that biosimilars demonstrate pharmacokinetic and pharmacodynamic equivalence to an approved reference product. The biosimilarity approval pathway may provide an alternative route for generic suppliers to enter the market.

Regulatory Uncertainty and Impact on Generic Suppliers

The ongoing patent dispute between BMS and Pfizer, and other generic companies, has been subject to litigation and regulatory review [4]. The outcome of this litigation may impact the availability and pricing of generic versions of Apixaban.

Key Suppliers and Manufacturers

BMS, Pfizer, and other companies, such as Mylan and Sandoz, have been involved in the development and marketing of Apixaban. These companies will be subject to the patent expiration date and regulatory uncertainty surrounding the medication.

Sources:
[1] Eliquis Label - Bristol-Myers Squibb Co.
[2] DrugPatentWatch: Eliquis - Apixaban
[3] FDA: Biosimilars and Interchangeable Biosimilars
[4] Bloomberg: Eliquis Patent Dispute